

Supplemental Appendix

The material accompanies “Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: an analysis from the Center for International Blood and Marrow Transplant Research” by Hemant S. Murthy et al.

Supplementary Content

Supplementary Table 1: Univariate analysis

Supplementary Table 2: Causes of death

Supplementary Table 3: Full conditioning regimen list

Supplemental Table 1: Univariate analysis results
 Study population (N = 164)

Outcomes	N	Prob (95% CI)
Overall survival	164	
1-year		74.9 (68-81.3) %
3-year		57.9 (49.9-65.7) %
5-year		51.2 (42.5-59.8) %
Disease-free survival	163	
1-year		66.9 (59.5-73.9) %
3-year		48.8 (40.9-56.8) %
5-year		44.4 (36.2-52.8) %
Relapse	163	
1-year		16.6 (11.3-22.7) %
3-year		28.9 (22-36.3) %
5-year		32.2 (24.7-40.3) %
Non-relapse mortality	163	
1-year		16.6 (11.3-22.7) %
3-year		22.3 (16.1-29.2) %
5-year		23.3 (16.9-30.4) %
Chronic GVHD	163	
6 months		27.9 (21.2-35.1) %
1-year		45.5 (37.8-53.3) %
2-year		52.7 (44.8-60.6) %
3-year		54.4 (46.4-62.3) %

Supplemental Table 2. Cause of death

	N (%)
Total	72
Primary disease	29 (40)
GVHD	16 (22)
Infection	6 (8)
Respiratory	4 (6)
Organ failure	7 (10)
Cardiac	1 (1)
Neurologic	4 (6)
Secondary malignancy	1 (1)
Missing	4 (6)

Supplemental Table 3. Conditioning Regimens

Conditioning regimen - no. (%)	
TBI/Cy	28 (17)
TBI/Cy/Flu	20 (12)
TBI/Cy/Flu/TT	1 (1)
TBI/VP	3 (2)
TBI/Mel	1 (1)
TBI/Flu	23 (14)
TBI/other(s)	1 (1)
Bu/Cy	16 (10)
Flu/Bu (MAC)	24 (15)
Flu/Bu (RIC)	16 (10)
Flu/Mel	26 (16)
Cy/Flu	4 (2)
Other(s)	1 (1)
In-vivo T-cell depletion - no. (%)	
No	136 (83)
Yes	28 (17)